Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients

被引:46
|
作者
Honda, Masaki [1 ]
Asonuma, Katsuhiro [1 ]
Hayashida, Shintaro [1 ]
Suda, Hiroko [1 ]
Ohya, Yuki [1 ]
Lee, Kwang-Jong [1 ]
Yamamoto, Hidekazu [1 ]
Takeichi, Takayuki [1 ]
Inomata, Yukihiro [1 ]
机构
[1] Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat & Pediat Surg, Kumamoto 8608556, Japan
关键词
diabetes mellitus; immunosuppression; liver-to-spleen ratio; living-donor liver transplantation; new-onset diabetes after transplantation; SINGLE-CENTER EXPERIENCE; HEPATITIS-C INFECTION; INSULIN-RESISTANCE; GLUCOSE-METABOLISM; GRAFT-SURVIVAL; MELLITUS; TACROLIMUS; CYCLOSPORINE; MANAGEMENT; CONVERSION;
D O I
10.1111/ctr.12103
中图分类号
R61 [外科手术学];
学科分类号
摘要
With the increased number of long-term survivors after liver transplantation, new-onset diabetes after transplantation (NODAT) is becoming more significant in patient follow-up. However, the incidence of new-onset diabetes after living-donor liver transplantation (LDLT) has not been well elucidated. The aim of this study was to evaluate the incidence and risk factors for NODAT in adult LDLT recipients at a single center in Japan. A retrospective study was performed on 161 adult patients without diabetes who had been followed up for threemonths after LDLT. NODAT was defined according to the 2003 American Diabetes Association/World Health Organization guidelines. The recipient-, donor-, operation-, and immunosuppression-associated risk factors for NODAT were assessed. Overall, the incidence of NODAT was 13.7% (22/161) with a mean follow-up of 49.8months. In a multivariate analysis, the identified risk factors for NODAT were donor liver-to-spleen (L-S) ratio (hazard ratio [HR]=0.022, 95% confidence interval [CI]=0.001-0.500, p=0.017), and steroid pulse therapy for acute rejection (HR=3.320, 95% CI=1.365-8.075, p=0.008). In conclusion, donor L-S ratio and steroid pulse therapy for acute rejection were independent predictors for NODAT in LDLT recipients. These findings can help in screening for NODAT and applying early interventions.
引用
收藏
页码:426 / 435
页数:10
相关论文
共 50 条
  • [31] New Onset Diabetes Mellitus in Living Donor Versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
    Yadav, A.
    Chang, Y. -H.
    Aqel, B.
    Byrne, T.
    Chakkera, H.
    Douglas, D.
    Mulligan, D.
    Rakela, J.
    Vargas, H.
    Carey, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 108 - 109
  • [32] Risk factors of post-endoscopic retrograde cholangiopancreatography pancreatitis among living-donor liver transplant recipients with biliary complications
    Espinosa, Wendell
    Chiu, Yi-Chun
    Kuo, Chung-Mou
    Liang, Chih-Ming
    Lu, Lung-Sheng
    Wu, Cheng-Kun
    ADVANCES IN DIGESTIVE MEDICINE, 2022, 9 (04) : 229 - 235
  • [33] Surgical site infection in living-donor liver transplant recipients: A prospective study
    Iinuma, Y
    Senda, K
    Fujihara, N
    Saito, T
    Takakura, S
    Kudo, T
    Kiuchi, T
    Tanaka, K
    Ichiyama, S
    TRANSPLANTATION, 2004, 78 (05) : 704 - 709
  • [34] Prognostic factors of living-donor liver transplantation for recipients with hepatorenal syndrome
    Kim, S. M.
    Park, C. -S.
    Kim, K. -H.
    Hwang, S.
    Ahn, C. -S.
    Moon, D. -B.
    Ha, T. -Y.
    Song, G. -W.
    Jung, D. -H.
    Park, G. -C.
    Yoon, Y. -I.
    Ha, S. -M.
    Kim, M.
    Lee, S. -G.
    TRANSPLANTATION, 2022, 106 (8S) : 50 - 50
  • [35] Transformational experiences in adult-to-adult living-donor liver transplant recipients
    Watanabe, Akemi
    Inoue, Tomoko
    JOURNAL OF ADVANCED NURSING, 2010, 66 (01) : 69 - 81
  • [36] Serum uric acid is an independent predictor of new-onset diabetes after living-donor kidney transplantation
    Tanaka K.
    Sakai K.
    Kushiyama A.
    Hara S.
    Hattori M.
    Ohashi Y.
    Muramatsu M.
    Kawamura T.
    Shishido S.
    Aikawa A.
    Renal Replacement Therapy, 4 (1)
  • [37] NEW IMPLEMENTATION OF A LIVING-DONOR LIVER TRANSPLANT PROGRAM.
    Braun, Felix
    Wilms, Christian
    Guenther, Rainer
    Honarpisheh, Human
    Kuechler, Thomas
    Weiler, Norbert
    Burdelski, Martin
    Broering, Dieter C.
    LIVER TRANSPLANTATION, 2008, 14 (07) : S102 - S102
  • [38] Sirolimus is associated with new-onset diabetes in kidney transplant recipients
    Johnston, Olwyn
    Rose, Caren L.
    Webster, Angela C.
    Gill, John S.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (07): : 1411 - 1418
  • [39] Effect of Pretransplant Hepatitis C Virus on the Development of New-Onset Diabetes Mellitus After Transplant in Egyptian Living-Donor Renal Allotransplant Recipients at Mansoura Urology and Nephrology Center
    Abbas, Mohamed H.
    Ismail, Mabrouk I.
    El Deeb, Salem A.
    Nagib, Ayman M.
    Hassan, Nabil M.
    Refaie, Ayman F.
    El Maghrabi, Hanzada M.
    Denewar, Ahmed A.
    Bakr, Mohamed A.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2015, 13 (01) : 26 - 34
  • [40] Long-term clinical outcomes and predictive factors for living-donor liver transplant recipients with acute liver failure
    Kim, H. Y.
    Yoon, Y. -I.
    Jung, D. -H.
    TRANSPLANTATION, 2023, 107 (09) : 224 - 225